Objectives, Strategies, and Background
Anxiety disorders are significant public health issues, affecting a greater proportion of individuals. They are the highly prevalent disorders associated with significant illness burden, thus, causing pain and suffering to the affected individuals and the people around them. Majorly, anxiety disorders such as Generalized Anxiety Disorder (GAD) and depression go under-recognized and undertreated in the primary care setting (Bandelow et al., 2022). Patients suffering from GAD often suffer somatic anxiety symptoms and psychic symptoms. Somatic anxiety symptoms may include muscle tension, dizziness, and nausea. Psychic symptoms may include insomnia, nervousness, and constant worry. These conditions are critical and may further lead to other illnesses; thus, they call for appropriate management. Both pharmacological and non-pharmacological treatment options are used to treat patients with such conditions. This project’s purpose is to evaluate the efficient treatment options available for patients with Generalized Anxiety Disorder (GAD) and Depression. Notably, the research aims to achieve this purpose by following the PICOT question: Among patients with Generalized Anxiety Disorder (GAD) and Depression (P), How does the use of anti-depressant (I) compared to relaxation and sleep therapy (C) Improve patient outcome (O) after an 8-week treatment period (T)
Treatment optimization is key to improving health outcomes. Besides, when offering treatment, efficiency is a critical factor of consideration to obtain positive health outcomes. GAD and depression may be treated through pharmacological or non-pharmacological treatment options (Strawn et al., 2018). The primary aim of this project is to determine the effectiveness and efficiency of using pharmacological treatment over non-pharmacological treatments for GAD and Depression. Second, the project aims to determine the appropriate strategy nurses should employ in managing GAD and depression cases to improve and sustain complete remission. Third, the project aims to determine the care outcomes of anti-depressant, relaxation, and sleep therapy among patients with GAD and depression.
To achieve the first objective, a study will be conducted in a primary care setting with two groups, Group 1 and Group 2. Group 1 will constitute patients with GAD and depression under anti-depressant treatment, and Group 2 will include patients with GAD and depression under relaxation and sleep treatment options. Through the eight weeks, the treatment process will be monitored. Data will be collected at the end of the period. The collected data will be analyzed to determine the most efficient treatment option.
In order to achieve the second objective, the other strategy would be to survey patients who have experienced remission from GAD and depression. According to Kong et al. (2020), the ultimate goal for GAD is remission. The contacts of the patients will be obtained from the primary care institutions, and permission will be sought before conducting the survey. Moreover, the participants will be asked questions specifically about their recovery and remission journey and the treatment option they used. The responses will be used to develop the appropriate initiative to enhance patient health outcomes.
To achieve the third objective, systematic reviews of randomized controlled studies will be considered to compare the treatment outcomes from previous studies. Recent studies on the treatment of GAD and depression, specifically the studies focusing on anti-depressant drug classes, will be considered. The outcomes of adult patients under GAD pharmacological treatment will be sought, considering recovery and remission rates. Generally, the health outcomes will be used to improve health outcomes through the initiative employed.
In most cases, anxiety disorders go unrecognized, thus, untreated, and at times, they are under-recognized and thus, undertreated in primary care. Despite the high prevalence of GAD and Depression among individuals, effectively diagnosing and treating patients with Generalized Anxiety Disorder and Depression remains challenging to most healthcare providers in the primary care setting. Besides, treatment is directed when the patient suffers complications resulting from the disorder or gets into a condition of distress (Bandelow et al., 2022). Health practitioners must be well versed in managing and treating such cases appropriately.
Treatment of GAD and depression patients majorly occur in the primary care setting. The healthcare providers use different treatment options to manage the conditions, including pharmacological and non-pharmacological interventions. On some occasions, nurses offer treatment that turns out to be inefficient. Besides, due to the chronic nature of the disorder, some patients may fail to respond fully to the treatment option (Ansara, 2020). Moreover, inefficient treatment options could hinder full recovery and lengthen the recovery process. 
GAD is chronic and associated with other significant health issues. Besides, treatment response for the disorder is often inadequate. Health practitioners must be well versed in the appropriate ways to manage and treat such cases. Understanding the proper, effective, efficient treatment plan to address these conditions is vital. The initiative employed in treating GAD and depression should improve the patient’s function and overall quality of life. To help improve the patient’s health function and overall quality of life through anti-depressants.
Generalized Anxiety Disorder and depression are the most common psychiatric disorders in primary care, although they are often undertreated. Satisfactory treatment response for the condition is vital to getting positive health outcomes and promoting complete remission. According to Garakani et all. (2020), studies have shown pharmacological treatment options efficient in treating GAD. Moreover, the initiative is associated with mild side effects such as nausea, headache, or constipation.
Ansara, E. D. (2020). Management of treatment-resistant generalized anxiety disorder. Mental Health Clinician, 10(6), 326-334.
Bandelow, B., Michaelis, S., & Wedekind, D. (2022). Treatment of anxiety disorders. Dialogues in clinical neuroscience.
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020). Pharmacotherapy of anxiety disorders: current and emerging treatment options. Frontiers in psychiatry, 1412. 
Kong, W., Deng, H., Wan, J., Zhou, Y., Zhou, Y., Song, B., & Wang, X. (2020). Comparative remission rates and tolerability of drugs for a generalized anxiety disorder: a systematic review and network meta-analysis of double-blind, randomized controlled trials. Frontiers in Pharmacology, 11, 580858.
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018). Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert opinion on pharmacotherapy, 19(10), 1057-1070.